[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 23.23.54.109. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Citations 0
Letters
December 1, 2004

Adolescents With Depression

Author Affiliations
 

Letters Section Editor: Robert M. Golub, MD, Senior Editor.

JAMA. 2004;292(21):2577-2579. doi:10.1001/jama.292.21.2577-b

To the Editor: While the TADS trial provides valuable data about a significant problem, we differ from the authors in their conclusion that treatment with fluoxetine should be made widely available, and that CBT in combination with fluoxetine should be “readily available as part of comprehensive treatment for depressed adolescents.”1 Because 2 of 3 outcome measures (Clinical Global Impressions [CGI] and Reynolds Adolescent Depression Scale [RADS]) show no significant difference between fluoxetine treatment alone and fluoxetine in combination with CBT, we do not see this study showing an advantage for the addition of CBT in all adolescents with MDD.

First Page Preview View Large
First page PDF preview
First page PDF preview
×